Zobrazeno 1 - 3
of 3
pro vyhledávání: '"H.-Tobias Arkenau"'
Autor:
Richard F. Kefford, Daniele Ouellet, Bo Ma, Peter Lebowitz, C. Martin Curtis, Samuel C. Blackman, Steven J. O'Day, Melvin T. Chin, Anna Pavlick, Michael Millward, Jeffrey R. Infante, Omid Hamid, Michael P. Brown, H.-Tobias Arkenau, Kevin B. Kim, Razelle Kurzrock, Georgina V. Long, Gerald S. Falchook
Purpose: Dabrafenib is a selective, potent ATP-competitive inhibitor of the BRAFV600-mutant kinase that has demonstrated efficacy in clinical trials. We report the rationale for dose selection in the first-in-human study of dabrafenib, including phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ced035f5a9c3adb4d6d3ba6e5392e18d
https://doi.org/10.1158/1078-0432.c.6522927.v1
https://doi.org/10.1158/1078-0432.c.6522927.v1
Autor:
Richard F. Kefford, Daniele Ouellet, Bo Ma, Peter Lebowitz, C. Martin Curtis, Samuel C. Blackman, Steven J. O'Day, Melvin T. Chin, Anna Pavlick, Michael Millward, Jeffrey R. Infante, Omid Hamid, Michael P. Brown, H.-Tobias Arkenau, Kevin B. Kim, Razelle Kurzrock, Georgina V. Long, Gerald S. Falchook
Table S1. Treatment-related adverse events of {greater than or equal to} grade 2 reported in at least 5% of patients by dose (3); Table S2. Summary of plasma dabrafenib pharmacokinetic parameters after single-dose administration of dabrafenib gelatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6954178cfdd02cc0e6fa2fbb6ada516a
https://doi.org/10.1158/1078-0432.22455123
https://doi.org/10.1158/1078-0432.22455123
Autor:
H-Tobias Arkenau, Sreeni Yalamanchili, Rachel E. Sanborn, Matthias Will, James J. Harding, Alexander I. Spira, Valentina Boni, Funda Meric-Bernstam, Pratigya Gautam, Rachel Li, Joyce F. Liu, Randy F. Sweis, Howard A. Burris
Publikováno v:
Cancer Research. 79:LB-185
Background: CX-2009 is a Probody™ drug conjugate (PDC) directed against CD166 (ubiquitously expressed in normal epithelium and overexpressed in carcinomas) that incorporates DM4, a potent but toxic microtubulin inhibitor (MTI). PDCs are preferentia